Company intelligence / Profile preview

Hillgene Biopharma

Ownership: Private
Development stage: Commercial

Overview

Hillgene has supported over 200 IIT clinical samples and filed INDs for eight projects. Two registered clinical projects are underway. The lead program is an autologous BCMA-targeted CAR-T cell therapy in Phase 2 trials. The company has also supported four projects with FDA & EMA orphan drug designations.

Therapeutic areas: OncologyImmunologyHematology
Modalities: CAR-T cell therapyTCR-T cell therapyStem cell therapyLentiviral vector-based therapies
Industry: Biotech

Partnerships

Supported technology transfer of clinical batches of CAR-T products to partnersCollaborated with Shenzhen Puruijin Biological Pharmaceutical Co., Ltd. on ribrecabtagene autoleucel

Beyond the preview

Go deeper on Hillgene Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hillgene Biopharma.

Explore the full profile